Expression Significance and Prognostic Value of GPR27 in Ovarian Cancer

Expression Significance and Prognostic Value of GPR27 in Ovarian Cancer

Background This study explored the prognostic role of GPR27 and its predictive value to platinum-based therapy in ovarian cancer.Material and methods A survival analysis of GPR27, and the therapeutic response to platinum in ovarian cancer was investigated using data from the cancer genome atlas (TCG...

Full description

Saved in:

Bibliographic Details
Main Authors:	Xiulan Peng, Yahong Cai, Bing Tang, Mingtao Zhang, Xia Wang
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2025-12-01
Series:	Journal of Investigative Surgery
Subjects:	G protein-coupled receptors ovarian cancer platinum treatment response predictive biomarker
Online Access:	https://www.tandfonline.com/doi/10.1080/08941939.2025.2491781
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Prognostic and Predictive Value of Systemic Inflammatory Markers in Epithelial Ovarian Cancer
by: Cem İdrisoğlu, et al.
Published: (2025-02-01)

THE VALUE OF CYTOREDUCTIVE SURGERY FOR ISOLATED LYMPH NODE RECURRENCE OF OVARIAN CANCER
by: H. I. Mamajonov, et al.
Published: (2020-07-01)

Investigating the effect of optimal cytoreduction in the context of platinum sensitivity in high‐grade serous ovarian cancer
by: Nicholas Cardillo, et al.
Published: (2022-10-01)

Survival Analysis of Ovarian Carcinosarcomas Depending on Platinum or Doxorubicin Based Adjuvant Chemotherapy
by: İlker Selçuk, et al.
Published: (2015-04-01)

Deep learning based on ultrasound images to predict platinum resistance in patients with epithelial ovarian cancer
by: Chang Su, et al.
Published: (2025-05-01)

Evaluation of platinum-free interval and chemotherapeutic effect of subsequent platinum-containing chemotherapy in patients with recurrent ovarian cancer initially treated with bevacizumab: SGSG018/Intergroup study
by: Tamaki Tanaka, et al.
Published: (2025-06-01)

Uncovering the role of Gpr45 in obesity regulation
by: Eva O. Karolczak, et al.
Published: (2025-08-01)

Preliminary study on the role and mechanism of ISG15 in exosomes in platinum resistance in ovarian cancer
by: TIAN Yanan, ZHENG Hui, YAN Tianqing, ZHANG Heng, LU Renquan, GUO Lin
Published: (2025-04-01)

RADIOTHERAPY IN MANAGEMENT OF BRCA-POSITIVE OVARIAN CANCER
by: T. V. Gorodnova, et al.
Published: (2017-09-01)

Ojeok-san enhances platinum sensitivity in ovarian cancer by regulating adipocyte paracrine IGF1 secretion
by: Jiong Ma, et al.
Published: (2024-12-01)

Mycobacteria Exploit Host GPR84 to Dampen Pro-Inflammatory Responses and Promote Infection in Macrophages
by: Reziya Wumaier, et al.
Published: (2025-01-01)

The Role of Initial Neutropenia and Neutrophil Dynamics in Personalizing Chemotherapy for Platinum-Resistant Ovarian Cancer
by: Radu-Dumitru Dragomir, et al.
Published: (2025-03-01)

Prognostic Significance of RBM3 Expression in Epithelial Ovarian Cancer: A Tissue Microarray-Based Study
by: Hyeong Chan Shin, et al.
Published: (2025-06-01)

The functional characteristics of GPR120 and its mechanism in preventing atherosclerosis
by: XIAO Jiahai, CHEN Gengji, ZHANG Pengfei, WU Tianyu, CHEN Xiaojia, ZHANG Zhizhen
Published: (2025-05-01)

The leadership of topotecan in the treatment of recurrent platinum-resistant ovarian cancer
by: K. E. Borisov
Published: (2014-07-01)

GPR43 regulates mitochondrial apoptosis through the cyclophilin D pathway in Alzheimer’s disease
by: Xiaoqin Wang, et al.
Published: (2025-06-01)

Expression and prognostic significance of MLH1 and GPRC5C in resectable hepatocellular carcinoma
by: Jun Lu, et al.
Published: (2025-07-01)

Expression changes and functional role of GPR110 in metabolic dysfunction-associated steatohepatitis
by: Ting HONG, et al.
Published: (2025-06-01)

PARP Inhibitors in Ovarian Cancer: Resistance Mechanisms, Clinical Evidence, and Evolving Strategies
by: Shant Apelian, et al.
Published: (2025-05-01)

LGR4 (GPR48): The Emerging Inter-Bridge in Osteoimmunology
by: Wonbong Lim
Published: (2025-03-01)

Mitotic MTH1 inhibitor karonudib kills epithelial ovarian cancer independent of platinum sensitivity
by: Rachel M. Hurley, et al.
Published: (2025-06-01)

HELQ upregulates PARP1 to drive platinum resistance and predict therapeutic response in ovarian cancer
by: Shuran Tan, et al.
Published: (2025-07-01)

Endogenous ligands of bovine FFAR2/GPR43 display distinct pharmacological properties
by: Tainara Cristina Michelotti, et al.
Published: (2025-08-01)

CT-based radiomics model to predict platinum sensitivity in epithelial ovarian carcinoma: a multicentre study
by: Mengge He, et al.
Published: (2025-07-01)

The Pharmacological Evidences for the Involvement of AhR and GPR35 Receptors in Kynurenic Acid-Mediated Cytokine and Chemokine Secretion by THP-1-Derived Macrophages
by: Katarzyna Sawa-Wejksza, et al.
Published: (2025-07-01)

CDK6 protects epithelial ovarian cancer from platinum‐induced death via FOXO3 regulation
by: Alessandra Dall'Acqua, et al.
Published: (2017-08-01)

Homologous recombination deficiency (HRD) tests for ovarian cancer: a multicenter French phase II study (HERO)
by: Raphaël Leman, et al.
Published: (2025-07-01)

Pembrolizumab combined with lenvatinib and metronomic cyclophosphamide in platinum-resistant ovarian cancer: a case report of durable clinical response
by: Guanlin Dai, et al.
Published: (2025-08-01)

The expression of immunohistochemical biomarkers PAX8 and CD117 in platinum resistant ovarian cancer at Saiful Anwar General Hospital, Malang, Indonesia
by: Robby Rinaldi Widodo, et al.
Published: (2025-04-01)

Loss of proton‐sensing GPR4 reduces tumor progression in mouse models of colon cancer
by: Leonie Perren, et al.
Published: (2025-08-01)

Renin–Angiotensin System Autoantibody Network in Parkinson’s Disease Patients
by: Carmen M. Labandeira, et al.
Published: (2025-06-01)

Recurrent ovarian cancer: prolongation of the platinum-free interval with the use of a weekly treatment regimen of hycamtin (topotecan)
by: E. G. Novikova, et al.
Published: (2014-07-01)

The efficacy and peripheral blood predictors in recurrent platinum-resistant ovarian cancer patients treated with immune checkpoint inhibitors
by: Baoyue Pan, et al.
Published: (2025-08-01)

The trajectory of conditional, recurrence-free, and long-term survival in a complete 10-year cohort of patients with advanced ovarian cancer
by: Nina Groes Kofoed, et al.
Published: (2025-03-01)

Ovarian cancer: new accents treatment of patients with platinum-sensitive relapses
by: A. G. Kedrova, et al.
Published: (2016-11-01)

Long-term effect of pegylated liposomal doxorubicin in recurrent platinum-resistant ovarian cancer: а clinical case
by: I. A. Pokataev, et al.
Published: (2015-11-01)

Influence of initial platinum-based chemotherapy on levels of He-4 protein and VEGF-A in primary tumors and metastases from ovarian cancer
by: E. M. Frantsiyants, et al.
Published: (2022-01-01)

Efficacy of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of platinum resistant recurrent ovarian cancer: a retrospective observational study
by: Alexandra R. Steck, et al.
Published: (2025-08-01)

The Quantitative Indices of ERCC1 Expression in Serous Ovarian Cancer Tissue and the Efficacy of First-Line Platinum-Based Chemotherapy
by: T. A. Bogush, et al.
Published: (2020-05-01)

Functional validation of somatic variability in TP53 and KRAS for prediction of platinum sensitivity and prognosis in epithelial ovarian carcinoma patients
by: Al Obeed Allah Mohammad, et al.
Published: (2025-12-01)